Your Health, We Care
Release date: 2024-08-23 17:52:22 Recommended: 99
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic strategy for patients with HR/HER2- advanced breast cancer.
Alpelisib in combination with fulvestrant is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer in postmenopausal women and men. This treatment option is particularly suitable for patients who have not responded adequately with previous endocrine therapy regimens, and these cancer types are confirmed by FDA-approved tests to ensure targeted treatment.
This precision treatment regimen has shown significant potential in clinical studies, so let's take a look at how well the combination of apelis and fulvestrant works.
Clinical studies have shown significant efficacy in improving progression-free survival (PFS) and overall response rate (ORR) in combination with fulvestrant.
In the study, 341 patients were tested for PIK3CA mutations, of which 336 were confirmed by an FDA-approved assay.
In these patients with PIK3CA mutations, the combination of apelis and fulvestrant has shown efficacy in prolonging progression-free survival (PFS) and improving overall response rate (ORR). No significant difference was shown in overall survival (OS) compared to the placebo group. For patients without PIK3CA mutations, no significant treatment benefit was observed.
These findings highlight the potential of Alpelisib in combination with fulvestrant in selected patient populations. Let's focus on what to look out for when using the drug.
Patients should pay attention to the following precautions when using Alpelisib, and monitor them regularly during treatment to reduce potential problems.
If the patient develops severe symptoms of hypersensitivity, such as rash, difficulty breathing, or facial swelling, Apelix should be discontinued immediately and used permanently. Patients are advised to be aware of these symptoms and seek medical attention as soon as they appear.
If the patient develops new or worsening respiratory symptoms, particularly hypoxia, cough, or dyspnea, treatment with Alpelisib should be discontinued immediately and evaluated for pneumonia. Patients with confirmed noninfectious pneumonia need to be permanently discontinued; Patients are advised to report any changes in respiratory symptoms promptly.
The above tips help patients to identify and cope with possible side effects in a timely manner, reducing the risks during treatment.
[Warm tips] Maintain regular communication with your doctor and pay attention to any abnormal changes in your body. In case of emergency, seek medical attention promptly.
